Open access · CC-BY
via OpenAlex
Anti-aging: senolytics or gerostatics (unconventional view)
Oncotarget · 2021 · ▲ 35 citations
Deregulated nutrient-sensing
Cellular senescence
Rapamycin / mTOR inhibition
Partial reprogramming (OSK)
Senolytics
Mouse
Abstract
// Mikhail V. Blagosklonny 1 1 Roswell Park Cancer Institute, Buffalo, NY 14263, USA Correspondence to: Mikhail V. Blagosklonny, email: [email protected] , [email protected] Keywords: geroscience; senolytics(definition); hyperfunction theory; aging; sirolimus Received: June 07, 2021     Accepted: July 05, 2021     Published: August 31, 2021 Copyright: © 2021 Blagosklonny. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Senolytics are basically anti-cancer drugs, repurposed to kill senescent cells selectively. It is even more difficult to selectively kill senescent cells than to kill cancer cells. Based on lessons of cancer therapy, here I suggest how to exploit oncogene-addiction and to combine drugs to achieve selectivity. However, even if selective senolytic combinations will be developed, there is little evidence that a few senescent cells are responsible for organismal aging. I also discuss gerostatics, such as mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) and other rapalogs, pan-mTOR inhibitors, dual PI3K/mTOR inhibitors, which inhibit growth- and aging-promoting pathways. Unlike senolytics, gerostatics do not kill cells but slow down cellular geroconversion to senescence(definition). Numerous studies demonstrated that inhibition of the mTOR pathways by any means (genetic, pharmacological and dietary) extends lifespan. Currently, only two studies demonstrated that senolytics (fisetin and a combination Dasatinib plus Quercetin) extend lifespan in mice. These senolytics slightly inhibit the mTOR pathway. Thus, life extension by these senolytics can be explained by their slight rapamycin-like (gerostatic) effects.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.18632/oncotarget.28049
- Canonical
- link ↗
- Fetched
- 2026-06-13 MST
Cite this
APA
Blagosklonny, M.V. (2021). Anti-aging: senolytics or gerostatics (unconventional view). <em>Oncotarget</em>. https://doi.org/10.18632/oncotarget.28049
Vancouver
Blagosklonny MV. Anti-aging: senolytics or gerostatics (unconventional view). Oncotarget. 2021. doi:10.18632/oncotarget.28049.
BibTeX
@article{mikhail2021Antiag,
title = {Anti-aging: senolytics or gerostatics (unconventional view)},
author = {Mikhail V. Blagosklonny},
journal = {Oncotarget},
year = {2021},
doi = {10.18632/oncotarget.28049},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Oncotarget 2023
Open access · CC-BY
Cancer prevention with rapamycin
Nature Cell Biology 2023
Open access · CC-BY
COPI vesicle formation and N-myristoylation are targetable vulnerabilities of senescent cells
Oncotarget 2017
Open access · CC-BY
From rapalogs to anti-aging formula
EBioMedicine 2019
Open access · CC-BY
Senolytics and senostatics as adjuvant tumour therapy
Aging Cell 2025
Open access · CC-BY
Senolytic treatment attenuates immune cell infiltration without improving <scp>IAV</scp> outcomes in aged mice
Nature Communications 2020
Open access · CC-BY